A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma

Trial Profile

A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs JS 001 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences
  • Most Recent Events

    • 27 Jan 2018 Treatment arm has been changed from 10 mg/kg humanized anti-PD-1 mAb to 360 mg humanized anti-PD-1 mAb Q3W.
    • 20 Jan 2018 Preliminary results (n=56) in patients with advanced oesophageal squamous cell carcinoma, presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Preliminary results (n=48) in patients with advanced gastric adenocarcinoma, presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top